Bicycle Therapeutics - BCYC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.86
  • Forecasted Upside: 125.82%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$20.75
▼ -1.35 (-6.11%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $46.86
▲ +125.82% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $46.86, with a high forecast of $65.00 and a low forecast of $32.00. The average price target represents a 125.82% upside from the last price of $20.75.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Bicycle Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00Low
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00Low
2/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$60.00Low
2/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00Low
2/21/2024HC WainwrightLower TargetBuy ➝ Buy$57.00 ➝ $55.00Low
12/20/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$44.00 ➝ $32.00Low
12/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$46.00 ➝ $43.00Low
11/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
11/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $40.00Low
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00Low
9/12/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$44.00Low
9/11/2023B. RileyUpgradeNeutral ➝ Buy$33.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00Low
8/4/2023Needham & Company LLCLower TargetBuy ➝ Buy$48.00 ➝ $46.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$57.00Low
8/4/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$46.00 ➝ $44.00Low
4/19/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00Low
3/1/2023Needham & Company LLCLower TargetBuy$72.00 ➝ $67.00Low
3/1/2023HC WainwrightReiterated RatingBuy$57.00Low
2/28/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00Low
2/27/2023Cantor FitzgeraldReiterated RatingOverweight$74.00Low
2/15/2023Needham & Company LLCReiterated RatingBuy$72.00Low
2/15/2023HC WainwrightReiterated RatingBuy$57.00Low
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$55.00Low
11/10/2022Piper SandlerBoost Target$37.00 ➝ $48.00Low
11/9/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $46.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/12/2022Morgan StanleyLower TargetEqual Weight$60.00 ➝ $45.00Low
9/8/2022JMP SecuritiesReiterated RatingBuy$70.00Low
8/31/2022CowenInitiated CoverageOutperformLow
8/31/2022CowenInitiated CoverageOutperformLow
8/22/2022SVB LeerinkBoost TargetOutperform$48.00 ➝ $50.00Low
8/5/2022SVB LeerinkLower TargetOutperform$69.00 ➝ $48.00Low
8/5/2022HC WainwrightLower TargetBuy$65.00 ➝ $57.00Low
7/28/2022BarclaysInitiated CoverageOverweight$30.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$60.00N/A
6/6/2022JMP SecuritiesReiterated RatingBuy$70.00Low
5/23/2022Piper SandlerLower TargetOverweight$76.00 ➝ $37.00Medium
4/13/2022B. RileyDowngradeBuy ➝ Neutral$62.00 ➝ $33.00Medium
4/12/2022Needham & Company LLCLower TargetBuy$85.00 ➝ $75.00High
4/7/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00 ➝ $80.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$100.00 ➝ $80.00N/A
3/3/2022JMP SecuritiesLower TargetMarket Outperform$85.00 ➝ $70.00High
3/2/2022B. RileyLower Target$72.00 ➝ $62.00Low
2/14/2022Morgan StanleyInitiated CoverageEqual Weight$60.00High
12/17/2021SVB LeerinkInitiated CoverageOutperform$70.00High
12/9/2021Needham & Company LLCInitiated CoverageBuy$85.00Medium
10/14/2021JMP SecuritiesBoost TargetOutperform$53.00 ➝ $85.00High
10/8/2021B. RileyBoost TargetBuy$56.00 ➝ $72.00High
10/8/2021Piper SandlerBoost TargetOverweight$46.00 ➝ $76.00High
10/8/2021OppenheimerBoost TargetOutperform$47.00 ➝ $65.00High
10/8/2021HC WainwrightReiterated RatingPositive ➝ Buy$39.00 ➝ $65.00High
10/7/2021Roth CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $65.00High
9/30/2021B. RileyInitiated CoverageBuy$56.00High
8/11/2021JMP SecuritiesReiterated RatingBuy$53.00Medium
7/13/2021Piper SandlerBoost TargetOverweight$39.00 ➝ $46.00High
5/11/2021OppenheimerBoost Target$38.00 ➝ $44.00Low
5/7/2021HC WainwrightBoost TargetBuy$31.00 ➝ $39.00Low
5/7/2021Piper SandlerBoost TargetOverweight$35.00 ➝ $39.00Low
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00Medium
1/20/2021Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $58.00Medium
1/15/2021OppenheimerBoost TargetOutperform$27.00 ➝ $38.00High
1/15/2021HC WainwrightBoost TargetBuy$28.00 ➝ $31.00N/A
12/3/2020HC WainwrightReiterated RatingBuy$28.00High
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
9/22/2020OppenheimerReiterated RatingBuy$27.00High
8/6/2020HC WainwrightReiterated RatingBuy$25.00Low
7/21/2020OppenheimerReiterated RatingBuy$27.00High
6/24/2020OppenheimerReiterated RatingBuy$27.00Low
6/11/2020OppenheimerInitiated CoverageOutperform$27.00High
5/8/2020HC WainwrightReiterated RatingBuy$25.00High
4/17/2020HC WainwrightInitiated CoverageBuy$25.00Low
11/14/2019Roth CapitalInitiated CoverageBuy$17.00 ➝ $17.00High
9/11/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$14.00High
(Data available from 6/19/2019 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/22/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/22/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/21/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 10 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/21/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2024
  • 9 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/20/2024
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024

Current Sentiment

  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Bicycle Therapeutics logo
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $20.75
Low: $20.57
High: $22.43

50 Day Range

MA: $22.83
Low: $20.75
High: $24.69

52 Week Range

Now: $20.75
Low: $12.54
High: $28.91

Volume

240,239 shs

Average Volume

403,323 shs

Market Capitalization

$887.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: B. Riley, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, JMP Securities, Morgan Stanley, and Needham & Company LLC.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $46.86, suggesting a possible upside of 125.8%. Cantor Fitzgerald has the highest price target set, predicting BCYC will reach $65.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $32.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503 and its investor relations email address is [email protected]. The official website for Bicycle Therapeutics is www.bicycletherapeutics.com. Learn More about contacing Bicycle Therapeutics investor relations.